Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients

…, N Arima, S Toji, I Masamoto, M Akimoto… - The Journal of …, 2006 - journals.aai.org
Human T cell lymphotropic virus type 1 (HTLV-1)-specific CTL are thought to be immune
effectors that reduce the risk of adult T cell leukemia (ATL). However, in vivo conditions of anti-…

Anti‐HTLV‐1 tax antibody and tax‐specific cytotoxic T lymphocyte are associated with a reduction in HTLV‐1 proviral load in asymptomatic carriers

M Akimoto, T Kozako, T Sawada… - Journal of medical …, 2007 - Wiley Online Library
Previous studies have suggested that higher anti‐human T‐lymphotropic virus 1 (HTLV‐1)
antibody titer and lower anti‐HTLV‐1 Tax antibody reactivity are risk factors for adult T‐cell …

Programmed death-1 (PD-1)/PD-1 ligand pathway–mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated …

T Kozako, M Yoshimitsu, M Akimoto, Y White… - Human immunology, 2011 - Elsevier
Human T-lymphotropic virus-1 (HTLV-1) causes HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) and adult T-cell leukemia–lymphoma in individuals with …

[HTML][HTML] HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells

…, Y Sakaki, K Matsushita, K Orihara, M Akimoto… - Experimental …, 2004 - Elsevier
OBJECTIVE: We examined the anti-tumor effect of pyrrolidinedithiocarbamate (PDTC) on
HTLV-1-infected T clones and the mechanism of HTLV-1 Tax protein inhibition of PDTC-…

[HTML][HTML] Association between bone mineral density of femoral neck and geriatric nutritional risk index in rheumatoid arthritis patients treated with biological disease …

…, H Tominaga, Y Arishima, G Jokoji, M Akimoto… - Nutrients, 2018 - mdpi.com
Treatment of rheumatoid arthritis (RA) with biological disease-modifying anti-rheumatic drugs
(bDMARDs) induces rapid remission. However, osteoporosis and its management remains …

[HTML][HTML] Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics

…, S Nagano, S Shigemizu, N Aoki, M Akimoto… - BMC Musculoskeletal …, 2015 - Springer
Background Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk
factors for osteoporosis during treatment with biologics. Methods Femoral neck bone mineral …

[HTML][HTML] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs

…, T Setoguchi, Y Arishima, H Ohtsubo, M Akimoto… - BMC Research …, 2017 - Springer
Objective Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors
for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-…

Target epitopes of HTLV‐1 recognized by class I MHC‐restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients …

T Kozako, M Akimoto, S Toji, Y White… - Journal of medical …, 2011 - Wiley Online Library
Human T-cell lymphotropic virus type I (HTLV-1) causes adult T-cell leukemia/lymphoma
and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The different …

Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus.

M Akimoto, K Matsushita, Y Suruga, N Aoki… - The Journal of …, 2007 - jrheum.org
OBJECTIVE: Human T lymphotropic virus type I (HTLV-I) may be associated with some
connective tissue autoimmune diseases, including systemic lupus erythematosus (SLE). To …

Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis

M Akimoto, S Yunoue, H Otsubo, T Yoshitama… - Modern …, 2013 - Taylor & Francis
Objective: The ability of the ImmuKnow (Cylex) assay to predict the risk of infection in rheumatoid
arthritis (RA) patients receiving synthetic or biological disease-modifying antirheumatic …